ReviewFrontiers in microbiology2023
Role of the gut microbiota in hematologic cancer.
Review in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 33 citations in OpenAlex.
- Fecal Microbiota Transplantation and Microbiota-Based Therapeutics in Allogeneic Hematopoietic Stem Cell Transplantation: Current Evidence and Future Directions.Clinical pharmacology and therapeutics · 2026Review
- One Target, Different Results: The Clinical Impact of Diagnostic Kit Choice inDiagnostics (Basel, Switzerland) · 2026Article
- The Gut-Bone Marrow Axis: Deciphering the Mechanistic Impact of Microbial Metabolites on Hematopoietic Homeostasis and Disorders.Microorganisms · 2026Review
- The gut microbiome in solid-organ and haematopoietic-stem-cell transplantation.Nature reviews. Microbiology · 2026Review
- The Role of Gut Microbiota in Acute Myeloid Leukemia.Journal of clinical medicine · 2026Review
- Gut Microbiota and Extraintestinal Cancers: Mechanistic Insights and Microbiome-Targeted Interventions.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Innovative approaches in the treatment of hematologic malignancies: the role of CRISPR-engineered microbiomes along the gut-immune axis in immunotherapy development.Cancer cell international · 2026Review
- The microbial metabolome: remodeling the therapeutic landscape in hematologic malignancies.NPJ biofilms and microbiomes · 2026Review
- The impact of gut microbiota on leukemia and prospects for novel therapies.Infectious medicine · 2026Review
- Therapeutic ecology of the fiber-microbiota-barrier axis in leukemia: resilience, immune recovery and pharmacomicrobiomics.Frontiers in microbiology · 2026Review
- Host-microbiome interactions in leukemia: mechanisms, treatment response, and clinical implications.Frontiers in cellular and infection microbiology · 2026Review
- The gut reservoir of carbapenem-resistant Enterobacterales: from dysbiosis and colonization to infection and decolonization, with a focus on patients with hematologic malignancies - a narrative review.Frontiers in cellular and infection microbiology · 2026Review
- Phage therapy and the microbiome in hematologic malignancies: opportunities, mechanisms, and early evidence.Journal of cancer research and clinical oncology · 2025Review
- Molecular Mechanisms and Therapeutic Perspectives of Gut Microbiota, Autophagy, and Apoptosis in Cholangiocarcinoma Pathophysiology.International journal of molecular sciences · 2025Review
- Commensal Bacteria Drive B-cell Lymphomagenesis in the Setting of Innate Immunodeficiency.Blood cancer discovery · 2025Article
- Mendelian randomization analysis reveals the causal relationship between immune cells and leukemia.Discover oncology · 2025Article
- The gastrointestinal mycobiome in inflammation and cancer: unraveling fungal dysbiosis, pathogenesis, and therapeutic potential.Medical oncology (Northwood, London, England) · 2025Review
- The Impact of Health-Promoting Lifestyle Behaviors on Gut Microbiota in Survivors of Hematological Cancer: A Scoping Review.Cancer reports (Hoboken, N.J.) · 2025Article
- Microbiota-reprogrammed phosphatidylcholine inactivates cytotoxic CD8 T cells through UFMylation via exosomal SerpinB9 in multiple myeloma.Nature communications · 2025Article
- Identification of intratumoral microbiome-driven immune modulation and therapeutic implications in diffuse large B-cell lymphoma.Cancer immunology, immunotherapy : CII · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematologic neoplasms represent 6.5% of all cancers worldwide. They are characterized by the uncontrolled growth of hematopoietic and lymphoid cells and a decreased immune system efficacy. Pathological conditions in hematologic cancer could disrupt the balance of the gut microbiota, potentially promoting the proliferation of opportunistic pathogens. In this review, we highlight studies that analyzed and described the role of gut microbiota in different types of hematologic diseases. For instance, myeloma is often associated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.